Metrion Biosciences Limited has made two senior appointments to its management team. Dr Edward Stevens joins the Company as head of Drug Discovery, and Dr Andrew Lightfoot as head of Medicinal Chemistry and Discovery Funding.    These appointments follow the expansion of Metrion’s internal drug discovery program, driven by funding from Innovate UK, to support research into potassium ion channel inhibitors.  The internal proprietary program will now be led by Dr Stevens and Dr Lightfoot, and is...